Clinical Trials ·
The TRIUMPH-Outcomes study aims to assess the effectiveness of retatrutide in reducing cardiovascular and kidney complications in adults with obesity. This clinical trial focuses on individuals with a body mass index (BMI) of 27 kg/m² or higher, and aims to provide insights into the long-term benefits of retatrutide over a five-year period.
What this source covers
The TRIUMPH-Outcomes study, registered under ClinicalTrials.gov, investigates the potential of retatrutide to significantly lower the incidence of serious heart-related complications and prevent the worsening of kidney function in adults living with obesity. The trial plans to enroll participants who have a BMI of 27 kg/m² or greater and either Atherosclerotic Cardiovascular Disease or chronic kidney disease. The duration of the study is approximately five years, during which participants will have up to 27 clinic visits with their study doctor.
Why it matters for Retatrutide research
This research is critical as it addresses two major health concerns associated with obesity: cardiovascular disease and chronic kidney disease. By focusing on these outcomes, the TRIUMPH-Outcomes study aims to provide valuable data on the efficacy of retatrutide as a therapeutic option for individuals at risk of these serious conditions. The results could enhance understanding of how retatrutide influences not only weight management but also broader cardiometabolic health.
Key findings or claims
- The study will evaluate the impact of retatrutide on cardiovascular complications.
- It will also assess the drug's ability to prevent the deterioration of kidney function.
- Participants will be adults with a BMI of 27 kg/m² or higher.
- The trial duration is set for about five years.
- Up to 27 clinic visits will be scheduled for each participant.
Context and prior work
Retatrutide is part of a new class of medications that target multiple pathways involved in metabolic regulation, including GLP-1, GIP, and glucagon receptors. Previous studies have indicated the potential of GLP-1 receptor agonists in improving cardiovascular outcomes and kidney health in patients with obesity. The findings from the TRIUMPH-Outcomes study could align with or expand upon existing literature, providing further evidence of the multifaceted benefits of retatrutide in managing obesity-related complications.
Practical takeaways for researchers
Researchers should closely monitor the outcomes of the TRIUMPH-Outcomes trial as it may yield significant insights into the long-term effects of retatrutide on cardiovascular and kidney health. The study's design, focusing on high-risk populations, could inform future clinical practices and guidelines. Additionally, understanding the mechanisms by which retatrutide operates may enhance the development of combination therapies targeting obesity and its associated comorbidities. For more information on dosing and potential outcomes, researchers can explore the retatrutide calculator.
FAQ
What is the primary goal of the TRIUMPH-Outcomes study?
The primary goal is to determine if retatrutide can significantly lower the incidence of serious heart-related complications and prevent worsening kidney function in adults with obesity.
Who is eligible to participate in the study?
Adults with a body mass index of 27 kg/m² or higher and either Atherosclerotic Cardiovascular Disease or chronic kidney disease are eligible for participation.
How long will the study last?
The study is expected to last for about five years, with participants attending up to 27 clinic visits.
Source: ClinicalTrials.gov · NCT06383390 · published 2026-04-20.